Stansberry Venture Technology is a monthly research advisory that gives subscribers access to venture capital-like opportunities in the stock market.
Editor Dave Lashmet looks for investments similar to the type available to the largest venture-capital firms, which make billions of dollars in profits by funding companies like Facebook and Twitter in their infancy…
What is Stansberry Venture Technology?
Stansberry Venture Technology Advisory is a monthly small-cap investing newsletter that aims to have a “venture capital” investing mindset, looking for high-risk opportunities for dramatic gains, often in tech or biotech.
In Stansberry Venture Technology, Dave Lashmet scours the public markets for little-known, small-cap companies that are producing the next wonder drug or technology. And you can access these opportunities even if you’re not a millionaire or a venture capitalist.
Dave is the perfect man to head up this effort. He is extremely plugged in to the technology and biotech sector. He’s an inventor with three active patents. He has developed, packaged, and sold his ideas to one of the largest consumer-electronics firms in the world.
— RECOMMENDED —
GET FREE 3-day Video Trading Series Showing You How to Start Making an Extra $1,000 a Month.
He has also spent the last 20 years working as an independent technology analyst, and close to a decade researching and writing about technology at five major universities.
Dave is one of the first employees Porter hired after launching Stansberry Research in August 1999.
In seven years between 1999 and 2006, David covered some of the most important technological innovations in history. Notably, his ID Biomedical recommendation returned 322% for subscribers… It’s still one of the 10 best-returning positions ever recommended in our company’s history. (You’ll find it listed in the Hall of Fame published at the end of every issue of our daily e-letter, the Stansberry Digest.)
He also did extensive early-stage research into groundbreaking tech (and medical tech) firms, including Intuitive Surgical, Autonomy (bought by HP), and Illumina. If you look up these stocks, you’ll see that they eventually went up hundreds of percent, and in some cases thousands, after he wrote about them.
And in Stansberry Venture, Dave is searching for the smallest and most promising firms out there… ones you’d likely never hear about (that is, until they get acquired). The goal is for subscribers to make five or 10 times their money on these speculations.
— RECOMMENDED —
Here’s how to prepare for the biggest stock market event of the decade.
Including the name and ticker of the best-performing stock of 2020.
Stansberry Venture Technology Review – DetailedView Inside
At Stansberry Venture Technology, they take an approach to investing that is responsible for some of the biggest investment gains in history.
They approach the market as venture capitalists.
Venture capitalists are the home run hitters of investing. They are the early backers in startup companies. Their successes become front-page news.
Before you even heard about Apple, venture capitalists were making early investments. By the time regular stock market investors heard about the company, venture capitalists had made more than 80,000% on their original investments. That’s a gain that turns every $10,000 invested into $8 million.
At Stansberry Venture Technology, they ’re doing something similar with one key difference…
Instead of recommending one big bet, they recommend lots of small bets across a dozen or more small, public companies with breakthrough products – the kind that could transform entire industries… and potentially return five to 10 times your money.
The stocks in this model portfolio are volatile… but if you can withstand occasional losses along the way, their moves can come up fast and be bigger than you’d ever imagine… just one big winner can make your retirement.
In fact, since Stansberry Research launched Venture Technology in 2014, nine recommendations in the portfolio have doubled (or more).
How do they find such big opportunities?
The secret is editor Dave Lashmet. Dave visits company headquarters and meets with CEOs, lab scientists, computer programmers – you name it – asking hundreds of questions to find the whole story.
The result is Stansberry Venture Technology – Stansberry’s most sophisticated research service.
— RECOMMENDED —
Want the chance to put $2,500, $5,000, $10,000, or more in your pocket every Thursday?
What do you get for your money with Stansberry Venture Technology Advisory?
Stansberry Venture Technology costs $5,500 per year. It’s a great deal, considering you’ll have the opportunity to turn hundreds into thousands – and thousands into millions.
Here’s what you’ll get with your subscription:
The Venture Technology Handbook. This comprehensive guide will tell you everything you need to know about our investing philosophy.
Special Readers-Only Reports: In these in-depth guides, Dave reveals incredible opportunities and shares expert advice from the world of venture tech investing. You can immediately download these reports on our website the moment you gain access to Venture Technology.
12 Monthly Venture Technology Issues: This is where you’ll find Dave’s concise explanations of the latest happenings in venture investing, and the best ways to exploit the unique profit opportunities.
The Stansberry Digest: Every weekday, the Stansberry Research editorial team writes up notes on interesting situations taking shape in the markets. This daily e-letter will keep you up-to-date on what’s going on with the Stansberry Research family: what we got right… what we got wrong… what we have planned… and more.
Who is Dave Lashmet?
Dave Lashmet is editor of Stansberry Venture, an advisory service focused on the most important trend in the world – emerging technologies. He takes a “venture capitalist” approach to investing… seeking out small-cap speculative stocks with strong catalysts and outstanding breakout growth potential.
Dave undertakes intensive research to discover under-the-radar technology and medical companies with stunning catalysts for near-term growth. The stocks recommended in Stansberry Venture have the potential to double and triple in price. Dave is also a senior analyst to Stansberry’s Investment Advisory.